<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>37(1)</volume><submitter>Carrasco J</submitter><funding>Bayer Consumer Care AG</funding><journal>Advances in therapy</journal><pagination>300-315</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6979459</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.</pubmed_title><pmcid>PMC6979459</pmcid><pubmed_authors>Koerber C</pubmed_authors><pubmed_authors>Yoon J</pubmed_authors><pubmed_authors>Pietsch GA</pubmed_authors><pubmed_authors>Carrasco J</pubmed_authors><pubmed_authors>Bennison C</pubmed_authors><pubmed_authors>Nicolas MP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2025-04-22T20:29:49.046Z</modification><creation>2025-04-06T03:03:40.884Z</creation></dates><accession>S-EPMC6979459</accession><cross_references><pubmed>31728825</pubmed><doi>10.1007/s12325-019-01147-6</doi></cross_references></HashMap>